Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.45 |
| ▸ | TUBB | P07437 | 2/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435036 | 1.00 | LMNA (0.48) | LMNAALDH1A1HTTL3MBTL1THRB | |
| SCHEMBL5022997 | 0.90 | THRB (0.39) | LMNAALDH1A1HTTL3MBTL1THRB | |
| SCHEMBL4435044 | 0.89 | ALDH1A1 (0.47) | LMNAALDH1A1HTTL3MBTL1THRB | |
| SCHEMBL4422896 | 0.85 | TUBB4A (0.52) | LMNAALDH1A1THRBMEN1KMT2A | |
| SCHEMBL14277457 | 0.82 | THRB (0.41) | LMNAALDH1A1L3MBTL1THRBMEN1 | |
| SCHEMBL24750205 | 0.81 | MAPT (0.59) | LMNAALDH1A1HTTL3MBTL1THRB | |
| SCHEMBL4431892 | 0.81 | MAPT (0.48) | ALDH1A1MAPTTUBB1TUBB4ATUBB | |
| SCHEMBL13636845 | 0.81 | LMNA (0.38) | LMNAALDH1A1L3MBTL1THRBMEN1 | |
| SCHEMBL13624845 | 0.81 | MAPT (0.54) | LMNAALDH1A1HTTMEN1KMT2A | |
| SCHEMBL5023003 | 0.80 | PCNA (0.45) | LMNAALDH1A1HTTL3MBTL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008030892-A2 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030892-A2 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | TUBB, TUBA1C, TUBB1 | LMNA 1792/4885ALDH1A1 3322/4885HTT 1121/4885 |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | TUBB, TUBA1C, TUBB1 | LMNA 1792/4885ALDH1A1 3322/4885HTT 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.